http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020201915-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_356aa1a0ebfce59b19d07b4d13953826 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b4a80ac02f1ecd0e698ec665e9b36b6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 |
| filingDate | 2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b43aa23d608dfd0263f719117252969 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0d8da68bfd89e315ea4ee7e5792ca00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18afcaf41caae8e99bbb0510db9269ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0430200b7a8f8aaf4359950c67bf3706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_563d5cae45db42380059b70a3e641769 |
| publicationDate | 2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020201915-A3 |
| titleOfInvention | Compositions and methods for reducing amyloid beta formation on and composition therefore |
| abstract | The present invention provides methods for reducing amyloid beta formation and for treating diseases associated with the accumulation of amyloid beta., The present invention provides (1) A β aggregation inhibition by A β Oligomer / Fibril formation inhibition, (2) BACE-1 reduced a through β- Amyloidogenic Processing inhibition, (3) cerebral blood flow to the increase of the cell outer Αβ Monomer, Oligomer & Αβ Fibril / Plaque reduction, (4) NO / cGMP / PKG / CREB Pathway to the activation of Neuronal cell Death inhibition and Neurogenesis, Synaptogenesis, Angiogenesis promotion, (5) DKK-1 inhibition by Wnt Signaling in the activation of synaptic plasticity recovery and Αβ production Positive Feedback Loop for inhibition of APP generates reduced and Αβ accumulation suppression, (6) Autophagy activation by cells within Toxic Mirodenafil, Sildenafil, Vardenafil, Tadalafil, Udenafil, Dasantafil, and Avanafil for the treatment of inhibition of Αβ Fibril / Plaque formation through removal of Soluble Αβ Oligomer; and a Pharmaceutically Acceptable Salt, Solvate, and Hydrate in selected compounds key of ingredient containing drug compound composition, and this with the treatment method provided. |
| priorityDate | 2019-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.